LIVIVO - Search results -

Search results

Result 1 - 10 of total 106

Search options

Article ; Online: Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review.

Korn, Stephanie / Cook, Bill / Simpson, Lisa J / Llanos, Jean-Pierre / Ambrose, Christopher S

2023 Volume 40, Issue 7, Page(s) 2944–2964

Abstract: Introduction: Randomized controlled trials (RCTs) of biologics in patients with severe, uncontrolled asthma have shown differential results by baseline blood eosinophil count (BEC). In the absence of head-to-head trials, we describe the effects of ... ...

Abstract	Introduction: Randomized controlled trials (RCTs) of biologics in patients with severe, uncontrolled asthma have shown differential results by baseline blood eosinophil count (BEC). In the absence of head-to-head trials, we describe the effects of biologics on annualized asthma exacerbation rate (AAER) by baseline BEC in placebo-controlled RCTs. Exacerbations associated with hospitalization or an emergency room visit, pre-bronchodilator forced expiratory volume in 1 s, Asthma Control Questionnaire score, and Asthma Quality of Life Questionnaire score were also summarized. Methods: MEDLINE (via PubMed) was searched for RCTs of biologics in patients with severe, uncontrolled asthma and with AAER reduction as a primary or secondary endpoint. AAER ratios and change from baseline in other outcomes versus placebo were compared across baseline BEC subgroups. Analysis was limited to US Food and Drug Administration-approved biologics. Results: In patients with baseline BEC ≥ 300 cells/μL, AAER reduction was demonstrated with all biologics, and other outcomes were generally improved. In patients with BEC 0 to < 300 cells/μL, consistent AAER reduction was demonstrated only with tezepelumab; improvements in other outcomes were inconsistent across biologics. In patients with BEC 150 to < 300 cells/μL, consistent AAER reduction was demonstrated with tezepelumab and dupilumab (300 mg dose only), and in those with BEC 0 to < 150 cells/μL, AAER reduction was demonstrated only with tezepelumab. Conclusion: The efficacy of all biologics in reducing AAER in patients with severe asthma increases with higher baseline BEC, with varying profiles across individual biologics likely due to differing mechanisms of action.
MeSH term(s)	Humans ; Eosinophils ; Anti-Asthmatic Agents/therapeutic use ; Biological Products/therapeutic use ; Asthma/drug therapy ; Leukocyte Count ; Eosinophilia/drug therapy ; Double-Blind Method
Chemical Substances	Anti-Asthmatic Agents ; Biological Products
Language	English
Publishing date	2023-05-26
Publishing country	United States
Document type	Systematic Review ; Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	632651-1
ISSN	1865-8652 ; 0741-238X
ISSN (online)	1865-8652
ISSN	0741-238X
DOI	10.1007/s12325-023-02514-0
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2101: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Reply to the Letter Entitled "FeNO Variability when Using Different Analyzers at the Joint ATS/ERS Guideline Cutoff".

Korn, Stephanie / Buhl, Roland

Respiration; international review of thoracic diseases

2019 Volume 99, Issue 1, Page(s) 94

MeSH term(s)	Breath Tests ; Exhalation ; Nitric Oxide
Chemical Substances	Nitric Oxide (31C4KY9ESH)
Language	English
Publishing date	2019-12-11
Publishing country	Switzerland
Document type	Letter ; Comment
ZDB-ID	206674-9
ISSN	1423-0356 ; 0025-7931
ISSN (online)	1423-0356
ISSN	0025-7931
DOI	10.1159/000504631
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh II Zs.138: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Trotz Basistherapie sind immer noch zu viele Asthma-Patienten symptomatisch. Gespräch mit PD Dr. med. Stephanie Korn

Korn, Stephanie

Journal für Pharmakologie und Therapie

2015 Volume 24, Issue 2, Page(s) 60

Language	German
Document type	Article
ZDB-ID	1142782-6
ISSN	1432-4334
Database	Current Contents Medicine

In stock of ZB MED Cologne/Königswinter

Zs.A 3615: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The Treatment of Mild and Moderate Asthma in Adults.

Lommatzsch, Marek / Buhl, Roland / Korn, Stephanie

Deutsches Arzteblatt international

2020 Volume 117, Issue 25, Page(s) 434–444

Abstract: Background: Asthma is a chronic inflammatory airway disease that usually causes variable airway obstruction. It affects 5-10% of the German population.: Methods: This review is based on relevant publications retrieved by a selective search, as well ... ...

Abstract	Background: Asthma is a chronic inflammatory airway disease that usually causes variable airway obstruction. It affects 5-10% of the German population. Methods: This review is based on relevant publications retrieved by a selective search, as well as on national and international guidelines on the treatment of mild and moderate asthma in adults. Results: The goal of treatment is to attain optimal asthma control with a minimal risk of exacerbations and mortality, loss of pulmonary function, and drug side effects. This can be achieved with a combination of pharmacotherapy and non-drug treatment including patient education, exercise, smoking cessation, and rehabilitation. Pharmacohterapy is based on inhaled corticosteroids (ICS) and bronchodilators. It is recommended that mild asthma should be treated only when needed, either with a fixed combination of ICS and formoterol or with short-acting bronchodilators. For moderate asthma, maintenance treatment is recommended, with an inhaled fixed combinations of ICS and long-acting beta-mimetics, possibly supplemented with longacting anticholinergic agents. Allergen immunotherapy, i.e., desensitization treatment, should be considered if the allergic component of asthma is well documented and the patient is not suffering from uncontrolled asthma. Asthma control should be monitored at regular intervals, and the treatment should be adapted accordingly. Conclusion: The treatment of asthma in adults should be individually tailored, with anti-inflammatory treatment as its main component.
MeSH term(s)	Administration, Inhalation ; Adrenal Cortex Hormones ; Adult ; Anti-Asthmatic Agents/therapeutic use ; Asthma/drug therapy ; Drug Therapy, Combination ; Formoterol Fumarate ; Humans
Chemical Substances	Adrenal Cortex Hormones ; Anti-Asthmatic Agents ; Formoterol Fumarate (W34SHF8J2K)
Language	English
Publishing date	2020-09-03
Publishing country	Germany
Document type	Journal Article ; Review
ZDB-ID	2406159-1
ISSN	1866-0452 ; 1866-0452
ISSN (online)	1866-0452
ISSN	1866-0452
DOI	10.3238/arztebl.2020.0434
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Impact of short-term pausing of oral corticosteroids on blood eosinophil count in patients with severe asthma.

Biener, Leonie / Milger, Katrin / Suhling, Hendrik / Korn, Stephanie / Pizarro, Carmen / Skowasch, Dirk

Pneumologie (Stuttgart, Germany)

2022 Volume 77, Issue 6, Page(s) 357–362

Abstract: Background: The peripheral blood eosinophil count (BEC) is a well-established and easily accessible biomarker for asthma patients and crucial for the therapeutic decision regarding monoclonal antibody (mAB) therapy. Oral corticosteroid therapy ... ...

Title translation	Auswirkungen einer kurzzeitigen Unterbrechung der oralen Kortikosteroidtherapie auf die Anzahl der Eosinophilen im Blut bei Patienten mit schwergradigem Asthma bronchiale.
Abstract	Background: The peripheral blood eosinophil count (BEC) is a well-established and easily accessible biomarker for asthma patients and crucial for the therapeutic decision regarding monoclonal antibody (mAB) therapy. Oral corticosteroid therapy frequently hinders the correct evaluation of BEC in patients with severe asthma, but a discontinuation of such therapy frequently comes along with severe side effects. Therefore, we examined the effect of a short 24-hour pause of OCS treatment on BEC in patients with severe asthma and followed-up whether patients with a then increased eosinophil count benefited from mAB-therapy, as expected. Methods: In this multicentre study we retrospectively included 24 patients with severe asthma and OCS therapy and determined their BEC count. Ten patients, where BEC count was obtained in the morning before taking medication (a de-facto 24-hour OCS pause), were assigned to group 1. Fourteen patients, where BEC was obtained after OCS tapering were assigned to group 2. Those who then received mAB treatment were followed up for treatment response (OCS dose, annual acute exacerbations, increase in forced expiratory volume in one second [FEV Results: We included 24 patients with a median age of 60.5 [IQR: 17.3] years. Regarding all baseline characteristics except FEV Conclusion: After just a short 24-hour pause of OCS therapy it was possible to demask a relevant eosinophilia in asthma patients, without risking severe side effects. In this manner, we enabled the possibility of achieving successful targeted mAB-therapy, according to the patient's individual asthma phenotype.
MeSH term(s)	Humans ; Eosinophils ; Anti-Asthmatic Agents/therapeutic use ; Retrospective Studies ; Asthma/diagnosis ; Asthma/drug therapy ; Adrenal Cortex Hormones ; Eosinophilia/drug therapy
Chemical Substances	Anti-Asthmatic Agents ; Adrenal Cortex Hormones
Language	English
Publishing date	2022-11-16
Publishing country	Germany
Document type	Multicenter Study ; Journal Article
ZDB-ID	607630-0
ISSN	1438-8790 ; 0934-8387
ISSN (online)	1438-8790
ISSN	0934-8387
DOI	10.1055/a-1956-8800
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh II Zs.142: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 54: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS).

Milger, Katrin / Korn, Stephanie / Feder, Claudia / Fuge, Jan / Mühle, Andreas / Schütte, Wolfgang / Skowasch, Dirk / Timmermann, Hartmut / Suhling, Hendrik

Pneumologie (Stuttgart, Germany)

2023

Abstract: Background: The introduction of monoclonal antibodies (biologics) has revolutionized the therapy of severe asthma. Even though there is a response in the majority of patients, the degree of response varies. To date criteria for assessment of response ... ...

Title translation	Kriterien zur Evaluation des Ansprechens auf Biologika bei schwerem Asthma – der Biologics Asthma Response Score (BARS).
Abstract	Background: The introduction of monoclonal antibodies (biologics) has revolutionized the therapy of severe asthma. Even though there is a response in the majority of patients, the degree of response varies. To date criteria for assessment of response to biologics are not consistently defined. Aim: To define criteria for evaluation of response to biologics that are precise, simple and suitable for daily use in order to guide decision-making regarding continuation, switching or stopping of biological therapy. Methods: 8 physicians with large experience in this indication, supported by a data-scientist, developed a consensus on criteria to evaluate response to biologics in patients with severe asthma. Result: We developed a combined score based on current literature, own experience and practicability. It uses the main criteria exacerbations, oral corticosteroid (OCS) therapy and asthma control (asthma control test, ACT). We defined thresholds for "good response", "response" and "insufficient response" rated with a score of "2", "1" and "0" respectively: annual exacerbations ("0 or reduction ≥ 75 %", "reduction 50-74 %", "reductio < 50 %"), daily OCS dose ("stopping or reduction ≥ 75 %", "reduction 50-74 %", "reduction < 50 %"), asthma control ("ACT increase ≥ 6 or ≥ 3 with result ≥ 20", "ACT increase 3-5 with result < 20", "ACT increase < 3"). Additional individual criteria like lung function and comorbidities may be important for evaluation of response. We propose 3, 6 and 12 months timepoint for assessment of tolerability and response. Using the combined score, we developed a scheme to guide the decision whether switching the biologic should be considered. Conclusion: The Biologic Asthma Response Score (BARS) serves as objective and simple tool to evaluate response to biologic therapy using the three main criteria exacerbations, OCS use and asthma control. A validation of the score was initiated.
Language	English
Publishing date	2023-08-25
Publishing country	Germany
Document type	Journal Article
ZDB-ID	607630-0
ISSN	1438-8790 ; 0934-8387
ISSN (online)	1438-8790
ISSN	0934-8387
DOI	10.1055/a-2102-8128
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh II Zs.142: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 54: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study).

Korn, Stephanie / Milger, Katrin / Skowasch, Dirk / Schulz, Christian / Mohrlang, Cordula / Wernitz, Martin / Paulsson, Thomas / Hennig, Michael / Buhl, Roland

Journal of asthma and allergy

2023 Volume 16, Page(s) 541–552

Abstract: Purpose: The German Asthma Net (GAN) operates a Severe Asthma Registry that provides an overview of the clinical presentation and management of patients with severe asthma. Based upon data from the GAN registry, the MepoGAN study aimed to describe ... ...

Abstract	Purpose: The German Asthma Net (GAN) operates a Severe Asthma Registry that provides an overview of the clinical presentation and management of patients with severe asthma. Based upon data from the GAN registry, the MepoGAN study aimed to describe clinical profiles and treatment outcomes of patients who were treated with the anti-IL-5 monoclonal antibody mepolizumab (Nucala Patients and methods: The MepoGAN study is a descriptive retrospective non-interventional cohort study. Mepolizumab patients enrolled in the GAN registry were evaluated with results being described in two different data sets: Cohort 1 (n=131) started on mepolizumab when the patients entered the registry. Results were reported after 4 months of therapy. Patients in Cohort 2 (n=220) were on treatment with mepolizumab at the time of enrollment and follow-up data were collected after a further year of treatment. Outcome measures included asthma control, lung function, disease symptoms, OCS use, and exacerbations. Results: Patients enrolled in the registry who started on mepolizumab in Cohort 1 had a mean age of 55 years, were former smokers in 51% of the cases, had a mean blood eosinophil count of 500 cells/μL, and frequently had maintenance OCS use (55%). In this real-world setting, mepolizumab therapy was associated with a clinically relevant reduction in blood eosinophils (-445.7 cells/μL), OCS use (-30%), and improvement in asthma control. Fifty-five percent (vs 10% at baseline) of the patients reported controlled or partially controlled asthma 4 months after starting therapy. In patients who were already treated with mepolizumab at registry enrollment (Cohort 2), asthma control and lung function remained stable after a further year of observation. Conclusion: The GAN registry data confirm the effectiveness of mepolizumab in a real-world setting. Treatment benefits are maintained over time. While the asthma of patients treated in routine practice was more severe, the results observed with mepolizumab are broadly consistent with RCTs.
Language	English
Publishing date	2023-05-11
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	2494877-9
ISSN	1178-6965
ISSN	1178-6965
DOI	10.2147/JAA.S403286
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Kriterien zur Evaluation des Ansprechens auf Biologika bei schwerem Asthma – der Biologics Asthma Response Score (BARS).

Milger, Katrin / Korn, Stephanie / Feder, Claudia / Fuge, Jan / Mühle, Andreas / Schütte, Wolfgang / Skowasch, Dirk / Timmermann, Hartmut / Suhling, Hendrik

Pneumologie (Stuttgart, Germany)

2023 Volume 77, Issue 4, Page(s) 220–232

Title translation	Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS).
Abstract	Background: The introduction of monoclonal antibodies (biologics) has revolutionized the therapy of severe asthma. Even though there is a response in the majority of patients, the degree of response varies. To date criteria for assessment of response to biologics are not consistently defined. Aim: To define criteria for evaluation of response to biologics that are precise, simple and suitable for daily use in order to guide decision-making regarding continuation, switching or stopping of biological therapy. Methods: 8 physicians with large experience in this indication, supported by a data-scientist, developed a consensus on criteria to evaluate response to biologics in patients with severe asthma. Result: We developed a combined score based on current literature, own experience and practicability. It uses the main criteria exacerbations, oral corticosteroid (OCS) therapy and asthma control (asthma control test, ACT). We defined thresholds for "good response", "response" and "insufficient response" rated with a score of "2", "1" and "0" respectively: annual exacerbations ("0 or reduction ≥ 75 %", reduction 50-74 %", "reductio < 50 %"), daily OCS dose ("stopping or reduction ≥ 75 %", "reduction 50-74 %", "reduction < 50 %"), asthma control (ACT increase ≥ 6 or ≥ 3 with result ≥ 20", "ACT increase 3-5 with result < 20", "ACT increase < 3"). Additional individual criteria like lung function and comorbidities may be important for evaluation of response. We propose 3, 6 and 12 months timepoint for assessment of tolerability and response. Using the combined score, we developed a scheme to guide the decision whether switching the biologic should be considered. Conclusion: The Biologic Asthma Response Score (BARS) serves as objective and simple tool to evaluate response to biologic therapy using the three main criteria exacerbations, OCS use and asthma control. A validation of the score was initiated.
MeSH term(s)	Humans ; Anti-Asthmatic Agents/therapeutic use ; Asthma/diagnosis ; Asthma/drug therapy ; Biological Products/therapeutic use ; Adrenal Cortex Hormones
Chemical Substances	Anti-Asthmatic Agents ; Biological Products ; Adrenal Cortex Hormones
Language	German
Publishing date	2023-02-16
Publishing country	Germany
Document type	English Abstract ; Journal Article
ZDB-ID	607630-0
ISSN	1438-8790 ; 0934-8387
ISSN (online)	1438-8790
ISSN	0934-8387
DOI	10.1055/a-2014-4350
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh II Zs.142: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 54: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Long-Term Dupilumab Efficacy on Severe Exacerbations and Lung Function in Patients with Type 2 Asthma.

Papi, Alberto / Castro, Mario / Busse, William W / Langton, David / Korn, Stephanie / Xia, Changming / Soler, Xavier / Pandit-Abid, Nami / Radwan, Amr / Jacob-Nara, Juby A / Rowe, Paul J / Deniz, Yamo

Annals of the American Thoracic Society

2024 Volume 21, Issue 4, Page(s) 675–679

MeSH term(s)	Humans ; Antibodies, Monoclonal, Humanized/therapeutic use ; Asthma/drug therapy ; Lung ; Anti-Asthmatic Agents/therapeutic use ; Double-Blind Method
Chemical Substances	dupilumab (420K487FSG) ; Antibodies, Monoclonal, Humanized ; Anti-Asthmatic Agents
Language	English
Publishing date	2024-02-01
Publishing country	United States
Document type	Letter
ZDB-ID	2717461-X
ISSN	2325-6621 ; 1943-5665 ; 2325-6621
ISSN (online)	2325-6621 ; 1943-5665
ISSN	2325-6621
DOI	10.1513/AnnalsATS.202306-544RL
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5828: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: As-needed low-dose inhaled corticosteroid/formoterol therapy in patients with severe asthma included in the German Asthma Net cohort.

Hinze, Christopher Alexander / Ehmann, Rainer / Jandl, Margret / Milger, Katrin / Schmidt, Olaf / Schulz, Christian / Skowasch, Dirk / Welte, Tobias / Buhl, Roland / Hamelmann, Eckard / Idzko, Marco / Taube, Christian / Korn, Stephanie / Suhling, Hendrik

ERJ open research

2024 Volume 10, Issue 2

Abstract: After the GINA update in 2019, the proportion of SMART therapy increased with evidence for better disease control in SMART patients compared to SABA ... ...

Abstract	After the GINA update in 2019, the proportion of SMART therapy increased with evidence for better disease control in SMART patients compared to SABA alone
Language	English
Publishing date	2024-04-08
Publishing country	England
Document type	Journal Article
ZDB-ID	2827830-6
ISSN	2312-0541
ISSN	2312-0541
DOI	10.1183/23120541.00741-2023
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito